ArticlePloS one2023
Changes in gut microbial community upon chronic kidney disease.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- The effect of dietary fiber based on fermentability and viscosity on the gut microbiome composition in chronic kidney disease: a systematic review of experimental and clinical trials.Research square · 2026Article
- Research advancement on the correlation between gut microbiota and chronic kidney disease.Antonie van Leeuwenhoek · 2026Review
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease.Biomedicines · 2026Review
- Gut microbiota in chronic kidney disease-mineral and bone disorder: shared mechanisms, disease-specific signatures, and therapeutic prospects.Frontiers in endocrinology · 2026Review
- Integrated gut microbiota and metabolomics analysis of the effect of pomegranate peel powder on intestinal inflammation in broilers induced by high non-starch polysaccharides.Frontiers in immunology · 2026Article
- Microbial dysbiosis and predictive neuroactive functional profiles in paediatric neurogenic bladder: an exploratory machine learning-based approach.Frontiers in cellular and infection microbiology · 2026Article
- Distinct Gut Microbiome Signatures in Hemodialysis and Kidney Transplant Populations.Journal of clinical medicine · 2025Article
- High Schistosoma mansoni infection intensity is associated with distinct gut microbiota and low levels of systemic cytokines in children along the Albert-Nile, Northern Uganda.BMC microbiology · 2025Article
- Associations Between Uraemic Toxins and Gut Microbiota in Adults Initiating Peritoneal Dialysis.Toxins · 2025Article
- The impact of progressive chronic kidney disease on hepatic drug metabolism.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- The role of circulating zonulin levels in patients with chronic kidney disease stages 3 to 5 not on dialysis.Medicine · 2025Observational
- Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.World journal of gastroenterology · 2025Review
- The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease.Frontiers in microbiology · 2025Review
- Role of Metabolic Abnormalities During the Progression of Chronic Kidney Disease and Preventive Strategies.International journal of medical sciences · 2025Review
- Multi-Organ Microphysiological Systems Targeting Specific Organs for Recapitulating Disease Phenotypes via Organ Crosstalk.Small science · 2024Article
- Article
- Gut Microbiota in Patients Receiving Dialysis: A Review.Pathogens (Basel, Switzerland) · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing incidence and mortality of chronic kidney disease (CKD), targeted therapies for CKD have been explored constantly. The important role of gut microbiota on CKD has been emphasized increasingly, it is necessary to analyze the metabolic mechanism of CKD patients from the perspective of gut microbiota. In this study, bioinformatics was used to analyze the changes of gut microbiota between CKD and healthy control (HC) groups using 315 samples from NCBI database. Diversity analysis showed significant changes in evenness compared to the HC group. PCoA analysis revealed significant differences between the two groups at phylum level. In addition, the F/B ratio was higher in CKD group than in HC group, suggesting the disorder of gut microbiota, imbalance of energy absorption and the occurrence of metabolic syndrome in CKD group. The study found that compared with HC group, the abundance of bacteria associated with impaired kidney was increased in CKD group, such as Ralstonia and Porphyromonas, which were negatively associated with eGFR. PICRUSt2 was used to predict related functions and found that different pathways between the two groups were mainly related to metabolism, involving the metabolism of exogenous and endogenous substances, as well as Glycerophospholipid metabolism, which provided evidence for exploring the relationship between gut microbiota and lipid metabolism. Therefore, in subsequent studies, special attention should be paid to these bacteria and metabolic pathway, and animal experiments and metabolomics studies should be conducted explore the association between bacterial community and CKD, as well as the therapeutic effects of these microbial populations on CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.